Wildtype

Wildtype faces cultivated meat's universal cost-and-scale wall with the added difficulty of fish-cell culture, and a converted-brewery pilot serving a handful of fine-dining restaurants is a very long way from the volume and unit cost needed for a real business — a leap the entire category has failed to make after billions in aggregate spend. The political headwinds are already hitting it directly: Wildtype's Texas restaurant partner had to stop selling the salmon to comply with SB 261, and Wildtype joined Upside in suing Texas — but a January 2026 court declined to enjoin the ban, so it stands, and Florida, Nebraska, Mississippi, Alabama and Indiana have their own restrictions, foreclosing state after state regardless of FDA clearance. Cultivated-meat funding has collapsed toward zero as an investment category, so the next capital raise to fund actual scale-up will be far harder than the 2022 Series B that supplied most of its $120M+. Premium sashimi positioning caps near-term volume by design, and the business must prove repeat restaurant demand at a price covering cell-culture costs before it can even attempt broader markets. First-mover regulatory clearance is a genuine asset, but it is being outrun by state legislatures, and a pilot-scale producer litigating for market access while funding dries up is a precarious place to be, however strong the backing looks on paper.